Ontology highlight
ABSTRACT:
SUBMITTER: Torres R
PROVIDER: S-EPMC4418347 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature
Torres Rosarelis R Kramer William G WG Baroldi Paolo P
Journal of clinical pharmacology 20150204 5
Tasimelteon is a circadian regulator that resets the master clock in the suprachiasmatic nuclei of the hypothalamus by binding to both melatonin MT1 and MT2 receptors making it a dual melatonin receptor agonist. Tasimelteon has been approved by the United States Food and Drug Administration for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). Two prospective, single-center, open-label studies evaluated the pharmacokinetics of tasimelteon and its main metabolites after a single 20 mg do ...[more]